請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57010
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳玉如(Yu-Ju Chen) | |
dc.contributor.author | Yi-Ting Wang | en |
dc.contributor.author | 王薏婷 | zh_TW |
dc.date.accessioned | 2021-06-16T06:32:52Z | - |
dc.date.available | 2019-09-03 | |
dc.date.copyright | 2014-09-03 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-05 | |
dc.identifier.citation | 1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 64, 9-29 (2014).
2. Nguyen, K.S., Kobayashi, S. & Costa, D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10, 281-289 (2009). 3. Nguyen, K.S. & Neal, J.W. First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics 6, 337-345 (2012). 4. Mitsudomi, T. Advances in target therapy for lung cancer. Jpn J Clin Oncol 40, 101-106 (2010). 5. Wheeler, D.L., Dunn, E.F. & Harari, P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7, 493-507 (2010). 6. Yarden, Y. & Sliwkowski, M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137 (2001). 7. Citri, A. & Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7, 505-516 (2006). 8. Jorissen, R.N. et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284, 31-53 (2003). 9. Marmor, M.D., Skaria, K.B. & Yarden, Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58, 903-913 (2004). 10. Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21, 2237-2246 (2003). 11. Kris, M.G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003). 12. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139 (2004). 13. Paez, J.G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004). 14. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101, 13306-13311 (2004). 15. da Cunha Santos, G., Shepherd, F.A. & Tsao, M.S. EGFR mutations and lung cancer. Annu Rev Pathol 6, 49-69 (2011). 16. Sakurada, A., Shepherd, F.A. & Tsao, M.S. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin Lung Cancer 7 Suppl 4, S138-144 (2006). 17. Riely, G.J. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung Cancer 60 Suppl 2, S19-22 (2008). 18. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786-792 (2005). 19. Hunter, T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80, 225-236 (1995). 20. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355-365 (2001). 21. Li, J. et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6, 291-299 (2010). 22. Klammer, M. et al. Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-668 (2012). 23. Li, J. et al. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol 9, 705 (2013). 24. Balbin, O.A. et al. Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nat Commun 4, 2617 (2013). 25. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007). 26. Schweppe, D.K., Rigas, J.R. & Gerber, S.A. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-296 (2013). 27. Olsson, N. et al. Grading breast cancer tissues using molecular portraits. Mol Cell Proteomics 12, 3612-3623 (2013). 28. Chelius, D. & Bondarenko, P.V. Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J Proteome Res 1, 317-323 (2002). 29. Chelius, D., Zhang, T., Wang, G. & Shen, R.F. Global protein identification and quantification technology using two-dimensional liquid chromatography nanospray mass spectrometry. Anal Chem 75, 6658-6665 (2003). 30. Cutillas, P.R., Geering, B., Waterfield, M.D. & Vanhaesebroeck, B. Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line. Mol Cell Proteomics 4, 1038-1051 (2005). 31. Quintana, L.F. et al. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics 8, 1658-1673 (2009). 32. Foster, L.J. et al. A mammalian organelle map by protein correlation profiling. Cell 125, 187-199 (2006). 33. Mallick, P. et al. Computational prediction of proteotypic peptides for quantitative proteomics. Nat Biotechnol 25, 125-131 (2007). 34. Old, W.M. et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 4, 1487-1502 (2005). 35. Marcantonio, M., Trost, M., Courcelles, M., Desjardins, M. & Thibault, P. Combined enzymatic and data mining approaches for comprehensive phosphoproteome analyses: application to cell signaling events of interferon-gamma-stimulated macrophages. Mol Cell Proteomics 7, 645-660 (2008). 36. Jaitly, N. et al. Robust algorithm for alignment of liquid chromatography-mass spectrometry analyses in an accurate mass and time tag data analysis pipeline. Anal Chem 78, 7397-7409 (2006). 37. Yang, F. et al. Applying a targeted label-free approach using LC-MS AMT tags to evaluate changes in protein phosphorylation following phosphatase inhibition. J Proteome Res 6, 4489-4497 (2007). 38. Wang, Y.T. et al. An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-5597 (2010). 39. Tsai, C.F. et al. Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-4069 (2008). 40. Breathnach, O.S. et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19, 1734-1742 (2001). 41. Chang, C.C. et al. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 96, 364-375 (2004). 42. Lu, X. & Zhu, H. Tube-gel digestion: a novel proteomic approach for high throughput analysis of membrane proteins. Mol Cell Proteomics 4, 1948-1958 (2005). 43. Han, C.L. et al. A multiplexed quantitative strategy for membrane proteomics: opportunities for mining therapeutic targets for autosomal dominant polycystic kidney disease. Mol Cell Proteomics 7, 1983-1997 (2008). 44. Tsai, C.F. et al. Sequential phosphoproteomic enrichment through complementary metal-directed immobilized metal ion affinity chromatography. Anal Chem 86, 685-693 (2014). 45. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2, 1896-1906 (2007). 46. Sugiyama, N. et al. Phosphopeptide enrichment by aliphatic hydroxy acid-modified metal oxide chromatography for nano-LC-MS/MS in proteomics applications. Mol Cell Proteomics 6, 1103-1109 (2007). 47. Savitski, M.M. et al. Confident phosphorylation site localization using the Mascot Delta Score. Mol Cell Proteomics 10, M110 003830 (2011). 48. Tsou, C.C. et al. IDEAL-Q, an automated tool for label-free quantitation analysis using an efficient peptide alignment approach and spectral data validation. Mol Cell Proteomics 9, 131-144 (2010). 49. Zeeberg, B.R. et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 4, R28 (2003). 50. Huang da, W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57 (2009). 51. Schwartz, D. & Gygi, S.P. An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets. Nat Biotechnol 23, 1391-1398 (2005). 52. Keshava Prasad, T.S. et al. Human Protein Reference Database--2009 update. Nucleic Acids Res 37, D767-772 (2009). 53. Amanchy, R. et al. A curated compendium of phosphorylation motifs. Nat Biotechnol 25, 285-286 (2007). 54. Lu, Y.T. et al. Proteomic profiles of bronchoalveolar lavage fluid from patients with ventilator-associated pneumonia by gel-assisted digestion and 2-D-LC/MS/MS. Proteomics Clin Appl 2, 1208-1222 (2008). 55. Cutillas, P.R. & Vanhaesebroeck, B. Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol Cell Proteomics 6, 1560-1573 (2007). 56. Xu, D. et al. Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics 7, 2215-2228 (2008). 57. Shi, R. et al. Analysis of the mouse liver proteome using advanced mass spectrometry. J Proteome Res 6, 2963-2972 (2007). 58. Chen, J.J. et al. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 61, 5223-5230 (2001). 59. Xia, X., Mariner, D.J. & Reynolds, A.B. Adhesion-associated and PKC-modulated changes in serine/threonine phosphorylation of p120-catenin. Biochemistry 42, 9195-9204 (2003). 60. Sieg, D.J. et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2, 249-256 (2000). 61. Bonne, S. et al. Defining desmosomal plakophilin-3 interactions. J Cell Biol 161, 403-416 (2003). 62. Shi, Y., Ouyang, P. & Sugrue, S.P. Characterization of the gene encoding pinin/DRS/memA and evidence for its potential tumor suppressor function. Oncogene 19, 289-297 (2000). 63. Ivaska, J., Pallari, H.M., Nevo, J. & Eriksson, J.E. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 313, 2050-2062 (2007). 64. Xu, L., Chen, S. & Bergan, R.C. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 25, 2987-2998 (2006). 65. Baek, D. et al. The impact of microRNAs on protein output. Nature 455, 64-71 (2008). 66. Hu, Z. et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11, 4646-4652 (2005). 67. Rangaswami, H., Bulbule, A. & Kundu, G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16, 79-87 (2006). 68. Bellahcene, A., Castronovo, V., Ogbureke, K.U., Fisher, L.W. & Fedarko, N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8, 212-226 (2008). 69. Desai, B., Rogers, M.J. & Chellaiah, M.A. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 6, 18 (2007). 70. Peck, D. & Isacke, C.M. Hyaluronan-dependent cell migration can be blocked by a CD44 cytoplasmic domain peptide containing a phosphoserine at position 325. J Cell Sci 111 ( Pt 11), 1595-1601 (1998). 71. Wai, P.Y. & Kuo, P.C. The role of Osteopontin in tumor metastasis. J Surg Res 121, 228-241 (2004). 72. Christensen, B. et al. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 282, 19463-19472 (2007). 73. Das, R., Mahabeleshwar, G.H. & Kundu, G.C. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 279, 11051-11064 (2004). 74. Dephoure, N. et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-10767 (2008). 75. Li, X., Huang, Y., Jiang, J. & Frank, S.J. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell Signal 20, 2145-2155 (2008). 76. Winograd-Katz, S.E. & Levitzki, A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 25, 7381-7390 (2006). 77. Laurent-Puig, P., Lievre, A. & Blons, H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 15, 1133-1139 (2009). 78. Hsueh, P.R. et al. Recurrent bacteremic peritonitis caused by Enterococcus cecorum in a patient with liver cirrhosis. J Clin Microbiol 38, 2450-2452 (2000). 79. Chang, C.H., Kuo, P.H., Hsu, C.H. & Yang, P.C. Persistent severe hypocapnia and alkalemia in a 40-year-old woman. Chest 118, 242-245 (2000). 80. Engelman, J.A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007). 81. Guix, M. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118, 2609-2619 (2008). 82. Browne, B.C. et al. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. FEBS J 280, 5237-5257 (2013). 83. Gioia, R. et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 118, 2211-2221 (2011). 84. Chang, T.H. et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med 183, 1071-1079 (2011). 85. Koizumi, F., Shimoyama, T., Taguchi, F., Saijo, N. & Nishio, K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116, 36-44 (2005). 86. Huang, M.H. et al. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol 7, 112-120 (2013). 87. Gazdar, A.F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1, S24-31 (2009). 88. Cardoso, A.P. et al. Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity. Oncogene 33, 2123-2133 (2014). 89. Jiang, X., Huang, F., Marusyk, A. & Sorkin, A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 14, 858-870 (2003). 90. Ahsan, A. et al. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 70, 2862-2869 (2010). 91. Sorkin, A., Helin, K., Waters, C.M., Carpenter, G. & Beguinot, L. Multiple autophosphorylation sites of the epidermal growth factor receptor are essential for receptor kinase activity and internalization. Contrasting significance of tyrosine 992 in the native and truncated receptors. J Biol Chem 267, 8672-8678 (1992). 92. Martins, L.R. et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 116, 2724-2731 (2010). 93. Kim, J.S. et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 13, 1019-1028 (2007). 94. Silva, A. et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118, 3762-3774 (2008). 95. Piazza, F.A. et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108, 1698-1707 (2006). 96. Prins, R.C. et al. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia 27, 2094-2096 (2013). 97. Bliesath, J. et al. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett 322, 113-118 (2012). 98. Hartmann, J.T., Haap, M., Kopp, H.G. & Lipp, H.P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 10, 470-481 (2009). 99. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41, D808-815 (2013). 100. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504 (2003). 101. Sakoda, L.C. et al. Germ line variation in nucleotide excision repair genes and lung cancer risk in smokers. Int J Mol Epidemiol Genet 3, 1-17 (2012). 102. Garcia-Carbonero, R. et al. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 14, e358-369 (2013). 103. Zhao, H. et al. Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer. PLoS One 8, e54674 (2013). 104. Fusco, A. & Fedele, M. Roles of HMGA proteins in cancer. Nat Rev Cancer 7, 899-910 (2007). 105. Wang, D.Z., Ray, P. & Boothby, M. Interleukin 4-inducible phosphorylation of HMG-I(Y) is inhibited by rapamycin. J Biol Chem 270, 22924-22932 (1995). 106. Sarhadi, V.K. et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 209, 206-212 (2006). 107. Liau, S.S., Ashley, S.W. & Whang, E.E. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma. J Gastrointest Surg 10, 1254-1262; discussion 1263 (2006). 108. Belton, A. et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 7, e30034 (2012). 109. Shah, S.N. et al. HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One 8, e63419 (2013). 110. Zhang, Y. et al. High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. Mol Cell Biochem 357, 363-371 (2011). 111. Hillion, J. et al. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res 7, 1803-1812 (2009). 112. Marko-Varga, G. et al. Personalized medicine and proteomics: lessons from non-small cell lung cancer. Journal of proteome research 6, 2925-2935 (2007). 113. Mok, T.S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947-957 (2009). 114. Beck, J.T., Ismail, A. & Tolomeo, C. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev (2014). 115. Romero-Garcia, S., Prado-Garcia, H. & Lopez-Gonzalez, J.S. Transcriptional analysis of hnRNPA0, A1, A2, B1, and A3 in lung cancer cell lines in response to acidosis, hypoxia, and serum deprivation conditions. Exp Lung Res 40, 12-21 (2014). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57010 | - |
dc.description.abstract | 蛋白質磷酸化參與調控許多細胞的基本過程,變異及過度活化的磷酸激酶可能調控癌症的訊息傳遞,可以藉此找出抗癌藥物的標靶蛋白。因此,本論文的目標為建立一個定量磷酸化蛋白質體學平台,並應用在肺癌的研究。在論文的第一個部分,我們發展了一個簡單的免標定磷酸化蛋白質定量法,結合自動化的金屬親和層析法和資訊輔助的SEMI(胜肽序列、滯留時間、質荷比及蛋白質內標)法則,並應用在具轉移性或抗藥性的肺癌細胞,以及不同種類的EGFR之病人組織個人化的磷酸蛋白質體分析。利用SEMI法則,我們以區間性的滯留時間同步化及比對跨越液相層析的識別胜肽,增加了可以定量的胜肽數目(由262條增加到1171條)。此外,以標準品蛋白為例,定量的準確度為10-12%,相關係數為0.99並且有4000倍的定量範圍;以定量體學示例,定量的變異性在99%的信心區間內低於1.9倍。
在應用的第一個部份,我們進行了非小細胞肺癌轉移相關且變異的磷酸化蛋白質體學。在不同種轉移能力的CL1肺癌細胞中,SEMI能針對854個蛋白中,1796條磷酸化胜肽得到定量結果,其中將近40%的磷酸化胜肽有大於兩倍的變化,而這些變化的磷酸化蛋白可比對到許多癌症轉移之磷酸化路徑,此研究呈現在轉移能力不同的細胞中,可能和其機制有關的磷酸化表現。 接著,我們利用SEMI策略進行對標靶藥物之抗藥性的肺癌細胞之磷酸化蛋白質體學分析。藉由比較具藥物靈敏度的PC9細胞及抗藥的PC9/gef細胞,並在抗藥的PC9/gef細胞中加入不同劑量的標靶藥物gefitinib,希望找出使抗藥性細胞回復藥物靈敏度的新標靶蛋白質。藉由磷酸化蛋白質體的差異,比較1548個蛋白中有4612條磷酸化胜肽被鑑定及定量,在這其中,161條胜肽在抗藥性的細胞中有較高表現,但在更多的藥物刺激後沒有變化,我們推測這些磷酸化蛋白可能參與細胞抗藥性。後續生化的實驗及訊息網絡證明了HMGA1為CK2的受質蛋白,並且可能是一個抗藥標靶蛋白。因此,我們抑制HMGA1在抗藥及可治療的肺癌細胞之表現,雖然沒有影響細胞生長,但在加入肺癌標靶藥物Gefitinib後,抗藥細胞的抗藥性則消失,證實HMGA1可以使具抗藥性之肺癌恢復為可治療細胞。我們成功地利用了抗藥的肺癌細胞之變異磷酸化蛋白質體,尋找標靶藥物所引起的抗藥性,且對於新的標靶蛋白提供了新的方向。 在應用的最後一個部份,我們利用SEMI免標定定量方法,分析30對癌症組織檢體以及鄰近的正常肺臟檢體;這些檢體之肺癌次形態有不同型態的EGFR包含了Del19-EGFR、L858R-EGFR和原生型EGFR。此分析共鑑定到來自2889個蛋白的10885條磷酸化胜肽,經由配對樣本均值推論及變異數分析的統計方法,這些差異性的磷酸化蛋白體數據可經由778條磷酸化胜肽組成膜組分成肺癌及肺臟兩個族群,此外,根據不同型態的突變或原生之EGFR,也可找出668/162條磷酸化胜肽 (p<0.05/p<0.01)分成三個族群(Del19-EGFR、L858R-EGFR和原生型EGFR)。在未來,利用此個人化的磷酸蛋白質體結果,我們希望鑑定到每種不同型態病人檢體之特異性磷酸化模組,進而找出潛在性的藥物標靶蛋白。 此論文結果顯示SEMI免標定定量法則為一個應用性廣的定量磷酸化蛋白質體學平台,可應用於多組數及多樣性的樣品,例如癌症細胞及癌症檢體,本論文在非小型細胞肺癌轉移、抗藥及不同型態的突變或原生EGFR之檢體分析結果,更提供了一個磷酸化蛋白體資料庫以更深入了解肺癌的訊息網絡。 | zh_TW |
dc.description.abstract | The abnormal protein kinase activity with its corresponding change in protein phosphorylation states has been implicated in tumor formation and cancer progression. The discovery of aberrant phosphorylation can lead to the design of kinase inhibitor, such as gefitinib, targeting mutated EGFR for cancer treatment. Therefore, we develop a quantitative phosphoproteomics method aiming for application on lung cancer. To reveal the lung-cancer associated phosphoproteome, in the first part of the thesis, we presented a simple label-free strategy combining an automated pH/acid-controlled IMAC procedure and informatics assisted SEMI (sequence, elution time, mass-to-charge, and internal standard) algorithm to address lung cancer metastasis, drug resistance and individualized phosphoproteomics study of different EGFR mutation subtypes. The SEMI strategy increased the number of quantifiable peptides from 262 to 1171 by using a fragmental regression algorithm for elution time alignment followed by peptide cross-assignment in all LC-MS/MS runs. In addition, the strategy demonstrated good quantitation accuracy (10-12%) for standard phosphoprotein, with the variation being less than 1.9 fold (within 99% confidence range) across proteomic scale. Reliable linear quantitative correlation (R2=0.99) can be obtained over 4000-fold dynamic concentrations.
In the first application, this approach was used to delineate metastasis-associated differential phosphoproteomics in NSCLC metastasis model. SEMI algorithm enabled quantification of 1796 unique phosphopeptides of 854 phosphoproteins from a series of NSCLC cell lines with varying degrees of invasiveness. Nearly 40% of the phosphopeptides showed >2-fold change in highly invasive cells; mapping of these differentially expressed phosphoproteins in multiple pathways related to cancer metastasis suggests that the site and degree of phosphorylation may have distinct patterns or functions in the complex process of cancer progression For the second application, we applied the label-free strategy to quantitatively profile the basal phosphoproteome and proteome of a drug resistant NSCLC model, including TKI-sensitive PC9, TKI-resistant PC9/gef and their dose-dependent responsiveness to gefitinib. Among the 4612 identified phosphopeptides from 1548 proteins, 161 phosphopeptides showed higher level in drug resistant cells but no response upon further gefitinib treatment, which was proposed to potentially correlate with drug resistance. Biochemical evidences and signaling network analysis revealed that HMGA1, the substrate protein to CK2, may be the potential drug resistant target in PC9/gef cells. Knockdown of HMGA1 did not affect cell survival, yet could reverse drug resistance in PC9/gef cells. The results provide new insights into drug resistant targets through the cellular signaling networks associated with the TKI-induced drug-resistant NSCLCs. In the final part of the thesis, the SEMI label-free approach was applied to analyze 30 NSCLC pairs of tumor tissues and their adjacent normal tissues from patients with different EGFR-dependent cancer subtypes including Del19-EGFR and L858R-EGFR and wild-type EGFR. A total of 10885 unique phosphopeptides from 2889 proteins were identified. Unsupervised statistical analysis categorized the differential phosphoproteomics patterns into differentiation of tumor and normal tissue samples as well as cancer tissue subtypes. This individualized phosphoproteomic screening could provide the opportunity to identify phosphorylation signature of individual patient with different disease phenotypes for potential drug target study in the future. We concluded that the SEMI label-free method is a universal quantitative phosphoproteomics platform for multiple-batch analysis for diverse materials including cell lines and tissues. The applications obtained in this study provided a big dataset for better understanding of the phosphorylation signaling in NSCLC metastasis, TKI drug resistant and the difference of EGFR mutations in tumor tissues. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T06:32:52Z (GMT). No. of bitstreams: 1 ntu-103-D98b46017-1.pdf: 4330503 bytes, checksum: 16b79fb86281352da3f7474e180b6beb (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 中文摘要 I
英文摘要 III List of Figures XI List of Tables XV CHAPTER 1 Introduction 1 1.1 Lung Cancer and EGFR Mutation-induced Drug Resistance 1 1.2 Application of Phosphoproteomics in Cancer Study 4 1.2.1. Phosphoproteomics Analysis on Human Cancer Tissue 6 1.3 The Advantage of Label-free Quantitative Approach 8 1.4 Objective 10 CHAPTER 2 Material and Method 14 2.1 Chemicals and material 14 2.2 Cell lines and cell culture 15 2.3 Total protein extraction from lung cancer cell and tissue 16 2.4 In Vivo Invasion Assay 17 2.5 Western blotting 18 2.6 Gel-assisted digestion 19 2.7 Tip-based pH/acid controlled IMAC 20 2.8 LC-MS/MS analysis 20 2.8.1 Phosphopeptides analysis by Waters Synapt HDMS 20 2.8.2 Phosphopeptides analysis by Orbitrap-XL 21 2.8.3 Phosphopeptides analysis by TripleTOF 5600 22 2.9 Data processing and protein identification 23 2.10 Quantitative Analysis by IDEAL-Q 25 2.11 Protein Annotation and Motif Analysis 26 2.12 Statistical Analysis 27 2.13 Lentivirus production and transduction 27 2.14 RNA extraction and RT-PCR 28 2.15 Sulforhodamine B (SRB) assay 29 CHAPTER 3 An Informatics-Assisted SEMI Strategy for Label-Free Quantitation 30 3.1 Informatics-Assisted SEMI Strategy for Label-Free Quantitation 30 3.2 SEMI Strategy Increases the Number of Quantifiable Phosphopeptides 33 3.3 Evaluation of Quantitation Accuracy, Precision, Reproducibility and Dynamic Range of SEMI Strategy 34 3.4 Differential Phosphoproteomics Profiles in Metastatic Lung Cancer Cell Model 39 3.5 Validation by Western Blotting for Subset of Phosphoproteins 41 3.6 Phosphoproteomics Identified Proteins Related to Cancer Metastasis 43 3.7 Summary of Regulated Phosphoproteins in Multiple Pathways Involved in Cancer Metastasis 44 CHAPTER 4 Identification of Potential Drug Resistant Target in Non-small-cell Lung Cancer by Label-free Quantitative Phosphoproteomics and Proteomics 49 4.1 Current Drug Resistant Target Discovery by Quantitative Phosphoproteomics 49 4.2 Gefitinib-induced drug resistance and the quantitative phosphoproteomics 50 4.3 Quantitation results of phosphoproteome and proteome dataset 53 4.4 Identification of potential drug resistant target 54 4.5 CK2 decreases cell survival in drug resistant NSCLCs 57 4.6 HMGA1 could regulate drug resistant in NSCLC 59 CHAPTER 5 EGFR-dependent Phosphoproteomic Signature Revealed by Individualized Cancer Tissue Analysis for Patient with Non-small-cell Lung Cancer 64 5.1 Evaluation of Protein Extraction Method and Buffer for Lung Tissue Phosphoproteomics 65 5.2 Individualized Non-small-cell Lung Cancer Tissue Analysis for EGFR-dependent Phosphoproteomic Signature 68 5.3 Phosphorylation Pattern Profiles and Protein-protein Interaction Network Analysis 70 CHAPTER 6 Conclusion and Future Perspective 73 References 75 | |
dc.language.iso | en | |
dc.title | 以磷酸化蛋白質體學研究肺癌的EGFR突變和抗藥性 | zh_TW |
dc.title | Phosphoproteomic Analysis of Non-small-cell Lung Cancer for EGFR Mutation and Drug Resistance Study | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 石濱泰(Yasushi Ishihama),戴桓青(Hwan-Ching Tai),邱繼輝(Kay-Hooi Khoo),潘思樺(Szu-Hua Pan),游佳融(Chia-Jung Yu) | |
dc.subject.keyword | 磷酸化蛋白質體學,免標定定量方法,肺癌,轉移,標靶藥物蛋白,抗藥性, | zh_TW |
dc.subject.keyword | phosphoproteomics,label-free quantitation,NSCLC,metastasis,drug resistance,EGFR mutation,individualized phosphoproteomics, | en |
dc.relation.page | 130 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-05 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 4.23 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。